Artificial Hip and Knee Joints Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented by Site (Hip Joints, Knee Joints), By End User (Hospitals & Surgery Centers, Orthopedic Clinics, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 14.64 Billion
CAGR (2026-2031)	3.13%
Fastest Growing Segment	Knee Joints
Largest Market	North America
Market Size (2031)	USD 17.61 Billion

Market Overview

The Global Artificial Hip & Knee Joints Market will grow from USD 14.64 Billion in 2025 to USD 17.61 Billion by 2031 at a 3.13% CAGR. Artificial hip and knee joints are prosthetic implants designed to replace damaged or diseased articular surfaces, aiming to restore musculoskeletal function and alleviate pain caused by degenerative conditions such as osteoarthritis. The market’s trajectory is fundamentally supported by the rapidly aging global population and the increasing demand for procedures that enable active lifestyles among senior demographics. According to the American Joint Replacement Registry’s 2024 Annual Report, primary total knee arthroplasty constituted 51.1% of the approximately 3.7 million procedural records analyzed, reflecting the substantial clinical volume and demand within this specific segment relative to other joint interventions.

However, market expansion confronts significant hurdles regarding stringent regulatory frameworks and reimbursement policies which can prolong product approval timelines. These rigorous compliance standards necessitate extensive clinical evidence and safety monitoring, thereby increasing development costs and potentially delaying the introduction of advanced implant technologies into cost-sensitive healthcare systems.

Key Market Drivers

The primary catalyst propelling the Global Artificial Hip & Knee Joints Market is the rapidly expanding global geriatric population and the associated rise in osteoarthritis prevalence, which fundamentally escalates the need for joint reconstruction. As life expectancy extends, the incidence of degenerative musculoskeletal conditions increases, necessitating surgical interventions to restore mobility and alleviate pain. This demographic pressure is evidenced by sustained procedural volumes in major healthcare systems; according to the National Joint Registry, September 2025, in the '22nd Annual Report', the registry recorded 134,652 knee procedures during the 2024 calendar year, highlighting the substantial clinical burden currently managed by orthopaedic providers.

Concurrently, advancements in robotic-assisted and computer-navigated surgery are driving market value by enhancing surgical precision and operational efficiency. These technologies are increasingly integrated into clinical workflows to optimize implant positioning and streamline pre-operative preparations, thereby fostering greater adoption among healthcare facilities. For instance, according to Zimmer Biomet Holdings, Inc., November 2025, in a press announcement regarding the 'ROSA Knee with OptimiZe', the system's new intelligent planning features have been shown to reduce surgical case planning time by an average of 46%, demonstrating the tangible efficiency gains offered by modern platforms. This technological momentum supports broader market health, as reflected by Stryker Corporation, October 2025, in the 'Q3 2025 Earnings Call', where the company reported a top-line growth of 10% in constant currency, driven significantly by the performance of their large joint and robotics portfolio.

Download Free Sample Report

Key Market Challenges

Stringent regulatory frameworks and reimbursement policies significantly hamper the growth of the Global Artificial Hip & Knee Joints Market by creating bottlenecks that delay revenue generation and inflate operational costs. When regulatory bodies enforce rigorous compliance standards, manufacturers must dedicate substantial resources to gathering extensive clinical evidence and navigating complex approval processes. This necessity diverts capital away from research and development, effectively stalling the commercialization of innovative prosthetic technologies. Consequently, companies face prolonged periods of uncertainty where capital is expended without immediate return, forcing them to be more risk-averse and selective regarding their product pipelines.

This impact is quantifiable in recent industry data which highlights the severity of these delays. According to MedTech Europe, in 2024, medical device manufacturers reported that the average time for Technical Documentation Assessment reached 21.8 months due to the complexity of complying with updated regulations. Such extended timelines directly restrict market access, causing manufacturers to delay product launches in key regions. As approval cycles lengthen, the industry experiences a tangible slowdown in the introduction of advanced joint replacement solutions, ultimately limiting the market’s expansion potential.

Key Market Trends

The Accelerated Shift to Outpatient and Ambulatory Surgical Centers is fundamentally restructuring the delivery of joint replacement care. This trend is driven by improvements in perioperative pain management and expedited recovery protocols, which allow eligible patients to be discharged safely within hours of surgery. Payers and healthcare systems are simultaneously incentivizing this migration to reduce hospitalization costs while maintaining clinical quality. This rapid operational change is evidenced by the surging volume of procedures in non-hospital settings. According to Surgery Partners, Inc., November 2025, in the 'Q3 2025 Earnings Call', the company reported that total joint surgeries in their ambulatory surgery centers grew 16% in the third quarter, underscoring the robust and sustained expansion of outpatient orthopedic services.

Concurrently, the Transition Toward Cementless Total Knee Arthroplasty Solutions is gaining traction as surgeons seek more durable, biological fixation methods for a younger and more active patient demographic. Unlike traditional cemented techniques, these advanced implants utilize porous surface coatings that encourage natural bone ingrowth, potentially reducing the risks associated with aseptic loosening and cement degradation over time. This clinical shift is quantitatively supported by national practice data. According to the American Academy of Orthopaedic Surgeons, November 2024, in the '2024 American Joint Replacement Registry Annual Report', cementless fixation accounted for 21.8% of all primary total knee arthroplasties recorded in 2023, reflecting a significant rise in the adoption of biologic fixation technologies.

Segmental Insights

The Knee Joints segment is currently recognized as the fastest-growing category within the global artificial hip and knee joints market. This accelerated expansion is primarily driven by the rising global prevalence of osteoarthritis and an aging population that increasingly requires surgical intervention to maintain mobility. Furthermore, the integration of robot-assisted technologies has improved surgical precision, which leads to better clinical outcomes and faster patient recovery. Continued product clearances by regulatory authorities, such as the U.S. FDA, for advanced implant designs further stimulate market activity, ensuring that the demand for knee replacement procedures consistently outpaces other joint reconstruction segments.

Regional Insights

North America maintains a dominant position in the global artificial hip and knee joints market, driven by a high prevalence of osteoarthritis and an aging demographic requiring surgical intervention. The region benefits from a well-structured healthcare system with robust reimbursement frameworks supported by the Centers for Medicare & Medicaid Services, which facilitate patient access to joint replacement procedures. Additionally, the local presence of major medical device manufacturers allows for consistent product availability. Regulatory oversight by the U.S. Food and Drug Administration further stabilizes the market by ensuring that new implants meet rigorous safety standards before commercialization.

Recent Developments

• In March 2025, Stryker showcased significant advancements in its robotic technology at the American Academy of Orthopaedic Surgeons Annual Meeting. The company introduced the Mako Total Hip with Advanced Primary and Revision capabilities, marking a first-to-market robotic solution for hip revision procedures. This new application was designed to streamline workflows and enhance surgeon confidence in complex cases by offering features such as augment and screw planning and intraoperative trajectory guidance. Additionally, the company highlighted the commercial availability of its fourth-generation Mako 4 system, which integrates advanced guidance technologies for hip and knee arthroplasty to offer a premium clinical experience.
• In March 2025, Zimmer Biomet Holdings, Inc. highlighted its latest orthopedic innovations at the American Academy of Orthopaedic Surgeons Annual Meeting. The presentation featured the company’s comprehensive hip portfolio, anchored by the Z1 Triple-Taper Femoral Hip System, which provides stability across various femoral anatomies. The company also introduced the newly cleared Persona Revision SoluTion Femur, specifically addressing the clinical needs of metal-sensitive patients in knee replacement. These developments were part of a broader showcase of technologies aimed at improving surgical efficiency and patient outcomes in joint reconstruction, positioning the company at the forefront of customer-centric innovation.
• In June 2024, DePuy Synthes announced that it had received 510(k) clearance from the U.S. Food and Drug Administration for its robotic-assisted solution for use in unicompartmental knee arthroplasty procedures. This regulatory approval expanded the application of the company's VELYS Robotic-Assisted Solution, which was previously indicated for total knee arthroplasty. The system is designed to provide surgeons with the ability to perform precise partial knee replacements without the need for a CT scan, thereby streamlining the surgical workflow. This advancement allows for greater personalization in knee reconstruction and supports the potential for improved outcomes in outpatient surgical settings.
• In February 2024, Smith+Nephew announced the introduction of new features for its CORI Surgical System at the American Academy of Orthopaedic Surgeons Annual Meeting. The updates to this handheld robotic-assisted platform were designed to further personalize surgery and optimize performance across the company's orthopaedic reconstruction portfolio. The system, which supports both knee and hip arthroplasty, was highlighted for its image-agnostic capabilities and its ability to improve surgical outcomes compared to conventional techniques. The company emphasized that these advancements aimed to enhance efficiencies in the operating room and support the growing demand for outpatient joint replacement procedures.

Key Market Players

• Zimmer Biomet
• Stryker
• Smith & Nephew
• Exactech
• Corin
• MicroPort
• Wright Medical
• B. Braun
• ConforMIS

By End User	By Region
Hospitals & Surgery Centers Orthopedic Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Artificial Hip & Knee Joints Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Artificial Hip & Knee Joints Market, By End User:

• Hospitals & Surgery Centers
• Orthopedic Clinics
• Others

• Artificial Hip & Knee Joints Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE